• The growing burden of neurological disease has intensified industry-wide interest in therapies capable of protecting neurons, preserving brain function and addressing disease progression at a biological level.
• Quantum BioPharma’s flagship pharmaceutical subsidiary, Lucid Psycheceuticals Inc., is advancing LUCID-MS, a patented new chemical entity being developed for an unmet need in multiple sclerosis.
• The company has also expanded its presence in a consumer ready product in the field of alcohol health and sobriety through its involvement with unbuzzd(TM), an innovative, clinically validated alcohol metabolism accelerator designed to help sober people up faster.

LOS ANGELES, CA - June 4, 2026 (NEWMEDIAWIRE) - Neurological disorders are increasingly recognized as one of the world’s most significant healthcare challenges as aging populations and rising disease prevalence place growing pressure on healthcare systems globally. According to the World Health Organization, neurological conditions are now the leading cause of illness and disability worldwide, affecting more than one-third of the global population. Despite advances in treatment, many currently approved therapies for neurodegenerative diseases primarily focus on symptom management rather than directly addressing underlying neurodegeneration, leaving substantial unmet medical needs across the sector. Current drugs for multiple sclerosis do not address loss of mobility and function which remains an unmet patient need today.

Against this backdrop, Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), is advancing a novel, new…

Read More

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

Forward Looking Statements

Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law

View the original release on www.newmediawire.com

This contant was orignally distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Quantum BioPharma (QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets.